Hydroxyphenyl propanoate compounds for tumour immunotherapy, compositions and uses thereof
OwnerDouglas J. MAHONEY, Md Saif Uddin SIKDARinventors
Life of this patent
Estimating the term…
Abstract
The present application relates to the use of hydroxyphenyl propanoate compounds of Formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts, solvates and/or ester prodrugs thereof, to increase anti-tumour immunity, to compositions comprising them, and their use, for example, in cancer immunotherapy. More particularly, the present application relates to compounds useful in the treatment of diseases, disorders, or conditions treatable by increasing anti-tumour immunity in a cell, such as cancer.
Claims28
-22. (canceled)
A method of increasing efficacy of immunotherapy in a patient with cancer comprising administering to the patient an effective amount of one or more compounds of Formula (V), a pharmaceutically acceptable salt, solvate and/or ester thereof:
- wherein:
- R8, R9 and R10 are, independently OH or H, provided at least one of R8, R9 and R10 is OH, or one of R8, R9 and R10 is selected from halogen, NR13R14 and C1-3 alkyl, and the other two of R8, R9 and R10 are H;
- R13 and R14 are independently selected from H and C1-3 alkyl;
- R11 is selected from H and =0;
- R12 is selected from H, C1-4alkyl and succinimide;
- and p is 1-4.
A method of increasing anti-tumour immunity, comprising administering to a patient in need thereof an effective amount of one or more compounds Formula (V), a pharmaceutically acceptable salt, a solvate and/or ester thereof:
- wherein:
- R8, R9 and R10 are, independently OH or H, provided at least one of R8, R9 and R10 is OH, or one of R8, R9 and R10 is selected from halogen, NR13R14 and C1-3 alkyl, and the other two of R8, R9 and R10 are H;
- R13 and R14 are independently selected from H and C1-3 alkyl;
- R11 is selected from H and ═O;
- R12 is selected from H, Ci.4alkyl and succinimide;
- and p is 1-4.
Dependencies are inferred from the claim text.